Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Wyeth Pharmaceuticals has announced that Pristiq, a new serotonin-norepinephrine reuptake inhibitor approved to treat adult patients with major depressive disorder, is now available in US retail pharmacies.
Subscribe to our email newsletter
The recommended dose of Pristiq (desvenlafaxine) is 50mg once daily. The company has initiated full-scale selling and educational efforts regarding Pristiq for physicians. Dosage adjustment (50mg every other day) is necessary, however, in patients with severe renal impairment or end-stage renal disease.
Philip Ninan, vice president, Wyeth Medical Affairs, Neuroscience, said: “The recommended therapeutic dose of Pristiq is 50mg once daily. Titration is not required to reach the recommended therapeutic dose.”